Baxter Presents Additional Data from Phase III Study of Immunoglobulin for Alzheimer's Disease at AAIC

  Baxter Presents Additional Data from Phase III Study of Immunoglobulin for
  Alzheimer's Disease at AAIC

Business Wire

DEERFIELD, Ill. -- July 16, 2013

Baxter International Inc. (NYSE:BAX) today presented additional data from the
Phase III Gammaglobulin Alzheimer’s Partnership (GAP) study, including select
analyses of subgroups, biomarker and imaging data, during the Alzheimer’s
Association International Conference (AAIC) in Boston, Mass. The GAP study was
conducted by Baxter and the Alzheimer’s Disease Cooperative Study (ADCS), a
clinical trial consortium supported by the United States National Institute on
Aging at the National Institutes of Health.

As previously disclosed, the GAP study did not meet its co-primary endpoints
of reducing cognitive decline and preserving functional abilities in patients
with mild to moderate Alzheimer’s disease. While the study was not powered to
demonstrate statistical significance among sub-groups within the study
population, additional post-hoc and exploratory analyses of the data are

Findings of the Additional Analyses To Date

On cognitive measures, an analysis of ApoE4 carrier patients who were treated
with the 400mg/kg biweeklydose (n=87) of immunoglobulin (IG), found a
statistically significant difference (p=0.012) in change from baseline in the
3MS score at 18 months versus placebo. Supplemental neuropsychological tests,
including Trails B (a test of executive function, including visual attention
and task switching), digit span backward and digit span forward (recall of a
series of numbers in the order provided or in reverse order), each showed a
numerical difference (p=0.073 and 0.082) in ApoE4 carriers.

Additional results from the analyses found:

  *A dose-dependent increase in levels of total IgG in the cerebrospinal
    fluid (CSF) from baseline (79% increase in the 400mg/kg dosing arm, 37% in
    the 200 mg/kg arm and 0% in placebo), suggesting Baxter’s IG passes
    through the blood brain barrier.
  *A dose-dependent increase in levels of antibodies related to amyloid
    present in Baxter’s IG as measured in the CSF (anti-oligomer and
    antifibril antibodies).
  *A dose-dependent reduction in plasma levels of amyloid beta (Aβ[1-42]) in
    Baxter IG treated patients relative to placebo (approximately 17%
    reduction in the 400 mg/kg arm, 6% in the 200 mg/kg arm, and -3% in
  *A reduction in brain fibrillar amyloid (as measured by PET scan using
    florbetapir [AV-45]) of 4.1% in patients who received IG at the 400mg/kg
    every 2 week dose (2.7% and 0.9% reductions in the 200mg/kg and placebo
    arms, respectively).
  *No effect observed in tau and phosphorylated tau levels in spinal fluid.

No new safety signals were identified associated with treatment in this
patient population, ages 50-89. The most common adverse reactions (observed in
at least 5 percent of patients) during treatment with IG were rash and
decreases in hemoglobin. There were no differences in the rate of
thromboembolic events in the treated groups versus placebo groups. There were
17 serious adverse reactions considered to be treatment-related in the study
(12 in the IG cohorts and five in the placebo cohort).

''The signals identified in the clinical and biological markers in select
subgroups in this analysis are intriguing and help contribute to a better
understanding of this disease,'' said Norman Relkin, MD, PhD, from Weill
Cornell Medical College and GAP Study leader.

Ongoing Research

Pre-planned and exploratory analyses on the GAP study findings are ongoing,
including reviews of subgroups and compilation of volumetric MRI imaging data,
and will be presented at a major medical meeting in the fall.

''We are currently collaborating with scientific experts in the field of
Alzheimer’s research to further explore these findings,'' said Ludwig Hantson,
Ph.D., President of Baxter’s BioScience business.

About the GAP Study

The GAP study was the largest placebo-controlled study of immunoglobulin, and
was designed to assess the safety and effectiveness of Baxter’s IG as a
potential treatment for signs and symptoms associated with Alzheimer’s
disease. The clinical trial included 390 patients with mild to moderate
Alzheimer’s disease across 45 centers in the U.S. and Canada. Patients were
randomized to receive Baxter’s IG at either 400 mg/kg or 200 mg/kg dosing
every two weeks for 18 months, or placebo. All patients were required to
maintain their treatment regimen of approved medications for Alzheimer’s
disease symptom management.

About Alzheimer’s Disease

Alzheimer’s disease (AD) is the most common type of dementia, a general term
for memory loss and other intellectual abilities serious enough to interfere
with daily life. The neurodegenerative disease is characterized by progressive
cognitive, functional, and behavioral impairment. Alzheimer’s is now the sixth
leading cause of death in the United States, with more than five million
people living with the disease today.

About IG

Immunoglobulin (IG) is made from purified human plasma, which is collected
from healthy volunteers. The immunoglobulin in plasma contains human
antibodies that protect the body against infection, offering important
immunomodulatory and anti-inflammatory properties that help treat rare
immune-related and neurological conditions. IG treatment is administered on an
ongoing basis to help patients maintain adequate levels of antibodies. IG has
been investigated as a treatment for Alzheimer’s disease and is not approved
for use in the treatment of the disease.

IMPORTANT RISK INFORMATION for Immunoglobulin (IG) Products

Immunoglobulin is made from human plasma and may carry a risk of transmitting
infectious agents. Immunoglobulin products have demonstrated the ability to
induce severe hypersensitivity reactions, thrombotic events, hemolytic anemia
and renal dysfunction, acute renal failure, osmotic nephrosis, and death in
pre-disposed patients. Immunoglobulin contains blood group antibodies that may
act as hemolysins. Hyperproteinemia, increased serum viscosity, and
hyponatremia may occur in patients receiving IG. Aseptic meningitis syndrome
has also been reported following intravenous administration of IG.
Non-cardiogenic pulmonary edema (TRALI) has been reported in patients
following treatment with IG products.

About Baxter International Inc.

Baxter International Inc., through its subsidiaries, develops, manufactures
and markets products that save and sustain the lives of people with
hemophilia, immune disorders, infectious diseases, kidney disease, trauma and
other chronic and acute medical conditions. As a global, diversified
healthcare company, Baxter applies a unique combination of expertise in
medical devices, pharmaceuticals and biotechnology to create products that
advance patient care worldwide.

This release includes forward-looking statements concerning the company’s
development program investigating the potential use of Baxter IG for the
treatment of mild to moderate Alzheimer's disease, including with respect to
ongoing additional analyses of the data from the GAP study. The statements are
based on assumptions about many important factors, including the following,
which could cause actual results to differ materially from those in the
forward-looking statements: completion of additional analyses of the data from
the GAP study; actions of regulatory bodies and other governmental
authorities; the development of other clinical evidence with respect to the
treatment of Alzheimer’s disease; and other risks identified in the company's
most recent filing on Form 10-K and other SEC filings, all of which are
available on the company's website. The company does not undertake to update
its forward-looking statements.


Baxter International Inc.
Media Contacts:
Brian Kyhos or Deborah Spak
(224) 948-5353
Investor Contacts:
Mary Kay Ladone, (224) 948-3371
Clare Trachtman, (224) 948-3085
Press spacebar to pause and continue. Press esc to stop.